Vonjo 100 mg capsule is a prescription medicine containing Pacritinib for oral use, marketed by Sobi, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at room temperature, below 30°C (86°F). Keep the bottle tightly closed…
Key facts
- Active ingredient (INN)
- Pacritinib
- Brand
- Vonjo
- Strength
- 100 mg
- Dosage form
- Capsule
- Route
- Oral
- Packs
- 40 cartons
- Marketing authorisation holder
- Sobi
- Manufacturer
- Sobi
- Origin register
- US FDA, United States
- Storage
- Store at room temperature, below 30°C (86°F). Keep the bottle tightly closed and protect from light. Store in original package.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 28 February 2022
- Identifiers
- RxCUI 2595248, 2595254DailyMed set ID 4b5ab444-0e1a-4984-99db-76ad11a298eeNDC 72482-100Application NDA208712
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 40 carton in 1 box / 1 bottle in 1 carton / 120 capsule in 1 bottle | 72482-100-12 | Sobi | 28 February 2022 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 28 February 2022 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Pacritinib is a kinase inhibitor. It is available as capsules for oral use. MedsAcross supplies Pacritinib for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about PacritinibFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Vonjo prescribing information (Sobi) · U.S. National Library of Medicine, DailyMed
Need Vonjo 100 mg capsule for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.